Your browser doesn't support javascript.
loading
Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC.
Chen, Qiuqiang; Jia, Gang; Zhang, Xilin; Ma, Wenxue.
Afiliación
  • Chen Q; Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University, Huzhou, Zhejiang, China.
  • Jia G; Department of Medical Oncology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Zhang X; Key Laboratory for Translational Medicine, The First Affiliated Hospital, Huzhou University, Huzhou, Zhejiang, China.
  • Ma W; Department of Medicine, Moores Cancer Center, and Sanford Stem Cell Institute, University of California San Diego, La Jolla, CA, United States.
Front Immunol ; 15: 1376045, 2024.
Article en En | MEDLINE | ID: mdl-38357544
ABSTRACT
[This corrects the article DOI 10.3389/fimmu.2023.1332057.].
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Immunol Año: 2024 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Immunol Año: 2024 Tipo del documento: Article País de afiliación: China